These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1350197)

  • 1. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia.
    Riederer P; Lange KW; Kornhuber J; Danielczyk W
    Arzneimittelforschung; 1992 Feb; 42(2A):265-8. PubMed ID: 1350197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis.
    Riederer P; Lange KW; Kornhuber J; Jellinger K
    J Neural Transm Suppl; 1991; 34():203-10. PubMed ID: 1687783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dopamine in schizophrenia and Parkinson's disease.
    Birtwistle J; Baldwin D
    Br J Nurs; 1998 Jul 23-Aug 12; 7(14):832-4, 836, 838-41. PubMed ID: 9849144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.
    Wang SJ; Yang TT
    Drug News Perspect; 2005 Nov; 18(9):561-6. PubMed ID: 16421629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon.
    Sawada H; Shimohama S; Tamura Y; Kawamura T; Akaike A; Kimura J
    J Neurosci Res; 1996 Jan; 43(1):55-62. PubMed ID: 8838574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural pharmacology of glutamate in the basal ganglia.
    Schmidt WJ; Bubser M; Hauber W
    J Neural Transm Suppl; 1992; 38():65-89. PubMed ID: 1491249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1996; 69():497-501. PubMed ID: 8615171
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
    Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Action mechanism of L-dopa: dopaminergic activation or glutamatergic inhibition?].
    Vamvakidès A
    Ann Pharm Fr; 1993; 51(1):8-15. PubMed ID: 8215122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
    Joyce JN; Millan MJ
    Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology.
    Fuxe K; Marcellino D; Rivera A; Diaz-Cabiale Z; Filip M; Gago B; Roberts DC; Langel U; Genedani S; Ferraro L; de la Calle A; Narvaez J; Tanganelli S; Woods A; Agnati LF
    Brain Res Rev; 2008 Aug; 58(2):415-52. PubMed ID: 18222544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.